Navigation Links
ThromboGenics Announces Business Update and 2008 Full Year Results
Date:3/12/2009

LEUVEN, Belgium, March 12 /PRNewswire-FirstCall/ --

- ThromboGenics Reports Pre-Tax Profit of EUR12.2 Million For 2008

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments that will make a real difference to patient care in a number of important therapeutic areas, is today issuing a business update and its financial results for the full year ending December 31, 2008.

During the last twelve months, ThromboGenics has made considerable progress across all aspects of its business culminating in the recent start of the Phase III clinical development program for its lead product microplasmin in back of the eye disease. The decision to start the Phase III program was based on the positive Phase II clinical results which were announced over the course of 2008.

In June 2008, ThromboGenics announced a further important corporate milestone, the signing of a high value strategic alliance with Roche for its novel anti-cancer antibody TB-403 (anti-PIGF). This deal, which generated an upfront payment of EUR30 million, has provided significant funding to allow ThromboGenics to invest in its other development programs.

The upfront payment from the Roche deal has enabled ThromboGenics to report a pre-tax profit of EUR 12.2 million in 2008.

Given its recent progress, ThromboGenics is confident that over the next eighteen months it will be able to generate significant shareholder value as it continues to maximize the value of its exciting product pipeline.

Business Highlights

Clinical Highlights

Microplasmin - Eye Disease: Positive results announced in Phase II clinical trials for back of the eye indications. Positive results were reported in ThromboGenics' Phase IIb (MIVI III) trial in patients with a number of back of the eye conditions. The trial show
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
2. ThromboGenics N.V.: Business Update
3. ThromboGenics Announces Half Year Results 2008
4. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
7. ThromboGenics N.V. - Business Update
8. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
9. ThromboGenics Announces 2007 Full Year Results
10. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
11. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 The National Necrotizing ... eyes—and life—were saved by doctors at Vanderbilt University Hospital ... NNFF, NovaBay Pharmaceuticals and Dr. John Crew , ... at Seton Medical Center in Daly City, ... a breakthrough approach, pioneered by Dr. Crew, that had ...
(Date:8/27/2015)... ... 2015 , ... Inc. Magazine released its annual list of the 5,000 fastest-growing ... growth for the three years through 2014. Being named to the Inc. 5000 list ... the country. , “We are thrilled to make the Inc. 5000 list for ...
(Date:8/26/2015)... 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended June 30, 2015. ... dollars and presented under International Financial Reporting Standards ... respect to our Oral Amp B program, rapidly ... said Andrew Rae , President & CEO ...
(Date:8/26/2015)... Md. , Aug. 26, 2015 Intrexon ... biology, announced today the closing of its previously announced ... full by the underwriters of their option to purchase ... public offering price of $41.00 per share.  The exercise ... shares of common stock sold by Intrexon to 5,609,756 ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... (NASDAQ: XTLB ; LSE: XTL; TASE: XTL) ... Officer, is scheduled to present at the,Acumen BioFin ... Mr.,Bentsur will present an overview of the Company ... compound for the treatment of,neuropathic pain. Mr. Bentsur,s ...
... HOUSTON, Oct. 26, 2007 -- The birth secret of ... a strand of DNA -- has been caught on ... University. An electron microscope video and computer simulations show ... distorted, unstable sheets of graphite, shedding loosely connected threads ...
... catalog of nanoscale technologies, nanowirestiny rows of conductor ... interest for their potential to build unique atomic-scale ... your local Nano Depot, manufacturers will need efficient, ... at the National Institute of Standards and Technology ...
Cached Biology Technology:XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health Care Conference 2Video shows buckyballs form by 'shrink wrapping' 2NIST demos industrial-grade nanowire device fabrication 2
(Date:8/20/2015)... 2015   Sensory, Inc ., a Silicon ... experience and security of consumer electronics through state-of-the-art ... its TrulySecure™ is the first multimodal ... FIDO Certified™. The FIDO (Fast Identification ... FIDO UAF (Universal Authentication Framework) 1.0 specifications, which ...
(Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
(Date:8/18/2015)... , Aug. 17, 2015 Research and ... of the "Global Biometric Authentication & Identification ... Estimation & Forecast, 2015-2020" report to their ... and identification systems market is expected to grow ... to 2020 and generate over $25 billion (approximately) ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... Advanced Iris Recognition Algorithm Detects and Compensates for ... ... Neurotechnology today,announced the addition of VeriEye iris recognition technology ... products. VeriEye SDK features an advanced iris recognition,algorithm that ...
... Stanley, Inc. (NYSE:,SXE), a leading provider of ... government, announced today that it has entered into ... an,engineering, intelligence operations and information technology services,company. The ... cash,subject to certain working capital and other adjustments ...
... AMBER Alert Safety Centers,Inc. announced today that the Company ... Fair, to be held at the Meadowlands Sport,Complex in East ... the entire family featuring rides, free entertainment, games, exhibits,shopping and ... Patterson -- Chief Executive Officer ...
Cached Biology News:New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 2New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems 3Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands 2AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands 3
...
... E. coli is an endoribonuclease that specifically ... that have 2-base, 3'-overhangs. Complete digestion ... 12-15 bp. RNase III can digest ... well as DuraScript™ RNA, produced using EPICENTRE's ...
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
Biology Products: